A multicenter randomized controlled trial of recombinant interferon‐α2b in patients with acute transfusion‐associated hepatitis C
Pietro Lampertico, Mariagrazia Rumi, Raffaella Romeo, Antonio Craxi, Roberta Soffredini, Daniela Biassoni, Massimo Colombo – 1 January 1994 – To assess whether interferon‐α might prevent non‐A, non‐B hepatitis from becoming chronic, 45 consecutive patients with transfusion‐associated hepatitis were enrolled in a randomized clinical trial. Thirty‐eight patients had hepatitis C virus infection, and 7 had non‐A, non‐B, non‐C hepatitis. Twenty‐six patients (22 with HCV) were given 3 MU of recombinant interferon‐α2b three times a week for 12 wk, whereas 19 (16 with HCV) were not.